Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. The Marketing Authorization approves axicabtagene ciloleucel for use in the 28 countries of the European Union, Norway, Iceland and Liechtenstein.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180827005248/en/
Axicabtagene ciloleucel is a chimeric antigen receptor T cell (CAR T) therapy, which harnesses a patient’s own immune system to fight certain types of blood cancer. The cell therapy has been proven to induce complete response (no detectable cancer) in a proportion of patients with relapsed or refractory DLBCL and PMBCL, which are aggressive forms of non-Hodgkin lymphoma (NHL).
“Axicabtagene ciloleucel is a new and exciting way of treating cancer that offers a new option to patients with DLBCL and PMBCL in Europe,” said Professor Gilles Salles, Head of Hematology, South Lyon Hospital Complex. “Many patients with these aggressive forms of non-Hodgkin lymphoma who have not responded to or failed commonly available treatment options have a very poor prognosis and there is an urgent need for new therapies.”
The Marketing Authorization Application (MAA) is supported by data from the ZUMA-1 trial of axicabtagene ciloleucel in adult patients with refractory aggressive NHL. In the single-arm trial, 72 percent of patients (n=73/101) who received a single infusion of axicabtagene ciloleucel responded to therapy, with 51 percent (n=52/101) achieving a complete response (as assessed by an independent review committee, median follow-up of 15.1 months). At one year following infusion, 60 percent of patients were alive (95% CI: 50.2, 69.2) and the median overall survival (OS) had not been reached (95% CI: not estimable [NE]).
Axicabtagene ciloleucel may cause side effects that are severe or life threatening, such as cytokine release syndrome (CRS) or neurological toxicities. In ZUMA-1, 12 percent of patients experienced Grade 3 or higher CRS and 31 percent experienced Grade 3 or higher neurologic toxicities. Overall 98 percent of patients recovered from CRS and/or neurologic adverse reactions. Treatment algorithms have been developed to manage some of the symptoms associated with both CRS and neurologic adverse reactions experienced by patients on axicabtagene ciloleucel.
The most common Grade 3 or higher adverse reactions include encephalopathy, unspecified pathogen infection, CRS, bacterial infection, aphasia, viral infection, delirium, hypotension and hypertension.
For full details on the Special Warnings and Precautions for Use and Adverse Reactions (including appropriate management) please refer to the EU Summary of Product Characteristics (SmPC).
“We are proud to be leading this frontier of cancer innovation that is bringing novel, personalized therapy to people living with these blood cancers,” said Alessandro Riva, MD, Gilead's Executive Vice President, Oncology Therapeutics & Head, Cell Therapy. “Our vision is for cell therapy to serve as the foundation for treating all cancer types. Today’s milestone is another step on this exciting and important journey.”
Axicabtagene ciloleucel was approved by the U.S. Food and Drug Administration on October 18, 2017.
Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that physicians may not see the benefits of prescribing axicabtagene ciloleucel for the treatment of DLBCL and PMBCL and the possibility of unfavorable results from additional clinical trials involving axicabtagene ciloleucel. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.
Full European Summary of Product Characteristics for Yescarta ® is available from the EMA website at www.ema.europa.eu .
Yescarta is a registered trademark of Gilead Sciences, Inc., or its related companies.
For more information on Kite, please visit the company’s website at www.kitepharma.com . Learn more about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Gilead Sciences, Inc.
Sung Lee, +1-650-524-7792
Nathan Kaiser, +1-650-522-1853
Sarah Swift, +44 (208) 587-2618
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AngloGold Ashanti plc Completes the Primary Listing of Its Ordinary Shares on the NYSE and Commences Trading25.9.2023 16:11:00 CEST | Press release
AngloGold Ashanti is pleased to announce that it has today completed its corporate restructuring, with a primary listing of its shares on the New York Stock Exchange (NYSE) and a corporate domicile in the UK. The corporate restructuring was first announced on 12 May of this year and approved by the shareholders of AngloGold Ashanti Limited on 18 August. “The move of our primary listing to the NYSE provides us with improved access to the world’s largest capital market and places us alongside the industry’s highest-valued gold companies,” said AngloGold Ashanti CEO Alberto Calderon. “This signifies an important new era for AngloGold Ashanti strengthening our corporate infrastructure as we continue to focus on taking performance from our world class asset base to the next level.” The ordinary shares of AngloGold Ashanti plc commenced trading on the NYSE today, 25 September 2023, maintaining the ticker symbol AU. Trading in the AngloGold Ashanti Limited American Depositary Shares (ADSs) on
PLIDCO Launches New Line of Hydrogen-Compatible Fittings25.9.2023 16:00:00 CEST | Press release
The Pipe Line Development Company (PLIDCO), the leader in pipeline leak repair and maintenance fittings, announced today a new range of products for use with hydrogen pipelines in response to the emerging transition toward hydrogen and other alternative energy sources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925622149/en/ PLIDCO Hydrogen-Compliant Fittings Brochure (Photo: Business Wire) Designed for onshore and subsea high-pressure emergency pipeline repairs and routine pipeline maintenance applications, PLIDCO’s products are ideal for hydrogen, oil, gas, water, chemical, steam, slurry and other piping systems. Its high-pressure fittings are designed and manufactured to meet the highest quality standards, following ASME/ANSI codes and adhering to a strict quality control program. “As the shift toward a hydrogen-based energy system gains traction, we anticipate an emerging need for pipeline maintenance and repair p
MESTEC Wins Oracle® Global Leaders ISV of the Year Award25.9.2023 15:30:00 CEST | Press release
MESTEC is excited to accept the Oracle Global Leaders ISV of the Year Award at this year’s Oracle CloudWorld Conference. At over 50% annual growth, MESTEC is leading the manufacturing software category and welcoming some of the world’s most innovative and valuable manufacturers to its pioneering SaaS MES platform. MESTEC’s primary focus on helping manufacturers gain performance across 80+ key manufacturing KPIs, along with its rapid deployment time, is fuelling customer migration to the platform. MESTEC is part of the Eyelit Group, an emerging leader in manufacturing software platforms. Together with Eyelit advanced manufacturing software, the two platforms are seeing especially strong demand in semiconductor, automotive, medtech, aerospace and defence, battery, and solar industries. The platforms support all key manufacturing workflows including asset management, factory and equipment integration, automation, manufacturing execution (MES), recipe management, quality management, planni
Seoul Semiconductor Exhibits LEDs for Future Vehicle Displays at SID Symposium in the US25.9.2023 15:00:00 CEST | Press release
Seoul Semiconductor (KOSDAQ:046890), a global optical semiconductor company, will participate in the Vehicle Displays & Interfaces Symposium 2023, organized by the Society of Information Display (SID), to be held in Detroit, USA, on September 26 and 27. During the event, the company will exhibit its LED products designed for future vehicle displays. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925760086/en/ Seoul Semiconductor's future vehicle display LED technology unveiled at SID (Graphic: Seoul Semiconductor) This exhibition will give visitors an opportunity to discover Seoul Semiconductor’s innovative LED technologies for future in-vehicle displays, such as ‘1515’, ‘Mini LED’ products for local dimming, and ‘WICOP Pixel’ microLED, in line with the evolution of automotive displays, which are increasing in size and resolution. “1515”, an ultra-small LED for local dimming Seoul Semiconductor will exhibit “1515”, an ult
ASMPT AMICRA and Teramount Collaborate to Advance Silicon Photonics Packaging25.9.2023 15:00:00 CEST | Press release
ASMPT AMICRA, a worldwide leading supplier of ultra-high precision die attach equipment that specializes in ultra-high precision die attach solutions, and Teramount Ltd, the leader in scalable fiber connectivity to chips, today announced a collaboration to address the challenge of connecting fibers to silicon photonic chips, to meet the ever-growing bandwidth demands in datacom and telecom applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925435797/en/ A close collaboration between Teramount and ASMPT AMICRA on fiber connectivity to silicon photonics chips (Photo: Business Wire) In the rapidly evolving fields of artificial intelligence and high-performance networking, one of the primary challenges has been to achieve seamless fiber-to-chip connectivity. The collaboration between the two companies, based on placement of Teramount’s pioneering wafer-level self-aligning optical elements on customer’s Silicon Photo